CN103313697B - 激酶抑制剂的口服制剂 - Google Patents

激酶抑制剂的口服制剂 Download PDF

Info

Publication number
CN103313697B
CN103313697B CN201180042122.1A CN201180042122A CN103313697B CN 103313697 B CN103313697 B CN 103313697B CN 201180042122 A CN201180042122 A CN 201180042122A CN 103313697 B CN103313697 B CN 103313697B
Authority
CN
China
Prior art keywords
preparation
inhibitors
kinases
polyethylene glycol
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180042122.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN103313697A (zh
Inventor
A.X.陈
Y.J.蔡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grace Of Ltd By Share Ltd
Verastem Inc
Original Assignee
Virri Sturm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virri Sturm Co Ltd filed Critical Virri Sturm Co Ltd
Publication of CN103313697A publication Critical patent/CN103313697A/zh
Application granted granted Critical
Publication of CN103313697B publication Critical patent/CN103313697B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201180042122.1A 2010-06-29 2011-06-28 激酶抑制剂的口服制剂 Expired - Fee Related CN103313697B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35969410P 2010-06-29 2010-06-29
US61/359,694 2010-06-29
PCT/US2011/042162 WO2012006081A1 (en) 2010-06-29 2011-06-28 Oral formulation of kinase inhibitors

Publications (2)

Publication Number Publication Date
CN103313697A CN103313697A (zh) 2013-09-18
CN103313697B true CN103313697B (zh) 2016-06-01

Family

ID=45441513

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180042122.1A Expired - Fee Related CN103313697B (zh) 2010-06-29 2011-06-28 激酶抑制剂的口服制剂

Country Status (10)

Country Link
US (1) US9375402B2 (enExample)
EP (1) EP2588081A4 (enExample)
JP (1) JP5936609B2 (enExample)
CN (1) CN103313697B (enExample)
AU (1) AU2011276552B2 (enExample)
CA (1) CA2803004A1 (enExample)
MX (1) MX340819B (enExample)
NZ (1) NZ604583A (enExample)
WO (1) WO2012006081A1 (enExample)
ZA (1) ZA201300009B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174946B2 (en) 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
RU2664700C2 (ru) 2012-05-10 2018-08-21 Пейнреформ Лтд. Депо-составы местного анестетика и способы их получения

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115369A2 (en) * 2007-03-16 2008-09-25 The Scripps Research Institute Inhibitors of focal adhesion kinase

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) * 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU1167702A (en) * 2000-10-11 2002-04-22 Cephalon Inc Compositions comprising modafinil compounds
TW200409629A (en) 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
US20080119515A1 (en) * 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos
CN101119976B (zh) 2005-02-18 2010-12-22 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物
EP1959926A1 (en) * 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
JP5592647B2 (ja) 2006-04-28 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 制御された析出による６，６−ジメチル−３−アザ−ビシクロ［３．１．０］ヘキサン−アミド化合物の析出および単離のための方法、ならびにこれを含む医薬処方物
PT2046292E (pt) * 2006-07-21 2010-04-26 Novartis Ag Formulações de éteres benzimidazolil-piridílicos
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
US8569298B2 (en) 2008-06-17 2013-10-29 Astrazeneca Ab Pyridine compounds
CN102648197A (zh) 2009-08-12 2012-08-22 铂雅制药公司 促进细胞凋亡和抑制转移的方法
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115369A2 (en) * 2007-03-16 2008-09-25 The Scripps Research Institute Inhibitors of focal adhesion kinase

Also Published As

Publication number Publication date
ZA201300009B (en) 2013-09-25
MX2012014982A (es) 2013-07-03
MX340819B (es) 2016-07-26
EP2588081A4 (en) 2014-12-10
US9375402B2 (en) 2016-06-28
JP2013529686A (ja) 2013-07-22
JP5936609B2 (ja) 2016-06-22
AU2011276552B2 (en) 2015-09-03
WO2012006081A1 (en) 2012-01-12
NZ604583A (en) 2015-04-24
US20140206692A1 (en) 2014-07-24
CA2803004A1 (en) 2012-01-12
EP2588081A1 (en) 2013-05-08
CN103313697A (zh) 2013-09-18
AU2011276552A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
US11020375B2 (en) Edaravone dosage form
CN101926757B (zh) 一种难溶性药物的液体组合物及其制备方法
AU2016245984B2 (en) Self-emulsifying formulations of DIM-related indoles
TW201124425A (en) Parenteral formulations of gemcitabine derivatives
JP2016504402A (ja) 抗がん剤および使用
JP5868414B2 (ja) タキソイドの医薬組成物
US20210346302A1 (en) Pharmaceutical Formulation
KR20150124984A (ko) 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
US20200384007A1 (en) Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof
CN114796110A (zh) 一种不含乙醇的难溶性药物浓缩液以及由其制备的胶束溶液
US6316497B1 (en) Self-emulsifying systems containing anticancer medicament
CN103313697B (zh) 激酶抑制剂的口服制剂
KR101413846B1 (ko) ４－［５－（４－메칠페닐）－３－（트리플루오로메칠）피라졸－１－일］벤젠술폰아미드 화합물 함유 액상 조성물
CN113979954B (zh) 一种替尼类抗肿瘤药物化合物及其制备方法和应用
KR20060130072A (ko) 레닌 억제제를 포함하는 마이크로에멀젼 예비농축액
CN112168781B (zh) 他克莫司的自微乳组合物及其制备方法
WO2014015153A2 (en) Compositions and methods for treating ewing's sarcoma and other disorders related to ews-fli1
KR20210128940A (ko) 자가나노유화 약물전달시스템을 이용한 니클로사마이드 함유 경구 투여용 조성물 및 이의 제조방법
CN113546044B (zh) 鲁拉西酮自微乳组合物及其制备方法
US20170165231A1 (en) Treating ewing's sarcoma and ews-fli1 related disorders
WO2025192799A1 (ko) 오시머티닙, 에토포사이드 및 도세탁셀이 봉입된 폴리비닐 카프로락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그래프트 공중합체 마이셀 및 이의 용도
KR20220124891A (ko) 나파모스타트 또는 이의 염을 포함하는 에멀젼을 포함하는 약제학적 제제 및 이의 제조 방법
WO2021162106A1 (ja) 溶解剤
AU2015261692A1 (en) Oral formulation of kinase inhibitors
CN109438321A (zh) 一种色氨酸衍生物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: VERASTEM INC.

Free format text: FORMER OWNER: ENKATA CO., LTD.

Effective date: 20140423

Owner name: ENKATA CO., LTD.

Free format text: FORMER OWNER: PONIARD PHARMACEUTICALS INC.

Effective date: 20140423

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140423

Address after: Massachusetts, USA

Applicant after: VERASTEM, Inc.

Address before: California, USA

Applicant before: The grace of the Limited by Share Ltd.

Effective date of registration: 20140423

Address after: California, USA

Applicant after: The grace of the Limited by Share Ltd.

Address before: Washington State

Applicant before: Boniad Pharmaceutical Co.,Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160601

Termination date: 20190628